Literature DB >> 14750168

Retinoblastoma protein in human renal cell carcinoma in relation to alterations in G1/S regulatory proteins.

Ylva Hedberg1, Börje Ljungberg, Göran Roos, Göran Landberg.   

Abstract

The retinoblastoma gene product (pRb) is the main substrate for cyclin-dependent kinases (CDKs) during the G1/S transition. Aberrations in cell cycle regulatory proteins, which have been observed in many malignancies, can theoretically cause increased phosphorylation of pRb due to unbalanced CDK activities. The expression and phosphorylation of pRb and potential associations to cell cycle aberrations in renal cell carcinomas (RCC) has only partly been clarified. We therefore evaluated the presence of pRb and the level of pRb-phosphorylation in 216 RCCs arranged in tissue microarrays by using different pRb-antibodies, including pRb-phosphospecific antibodies. Most RCCs (95%) expressed pRb, while cases with the low pRb levels, potentially indicative for pRb-inactivation, were few. In order to detect secondary alterations to a potential pRb-inactivation, the p16 expression was also monitored. None of the tumors exhibited increased p16 levels, confirming that pRb-inactivation is rare in RCC. Phosphorylated pRb was detected in approximately 50% of the RCCs, using Western blotting or immunohistochemistry. The immunohistochemical ppRb(ser807/811) levels were associated with high proliferation, cyclin D1, cyclin E and p27 protein content. Surprisingly, there was no association between pRb-phosphorylation and clinicopathological data. In summary, pRb seemed to be functional and aberrations in G1/S-regulatory proteins were associated with increased phosphorylation of pRb and proliferation. The data supports that pRb might be one of the main cell cycle regulators in RCC. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750168     DOI: 10.1002/ijc.11665

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas.

Authors:  Derek John Atkins; Christian Gingert; Christina Justenhoven; Gerd Emil Schmahl; Marcellus Stephanus Bonato; Hiltrud Brauch; Stephan Störkel
Journal:  Virchows Arch       Date:  2005-07-01       Impact factor: 4.064

2.  Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis.

Authors:  Xue-Jiao Lv; Li-Jing Zhao; Yu-Qiu Hao; Zhen-Zhong Su; Jun-Yao Li; Yan-Wei Du; Jie Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

3.  NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation.

Authors:  Amit Bera; Nandini Ghosh-Choudhury; Nirmalya Dey; Falguni Das; Balakuntalam S Kasinath; Hanna E Abboud; Goutam Ghosh Choudhury
Journal:  Cell Signal       Date:  2013-08-24       Impact factor: 4.315

4.  The prognostic value of cyclin D1 in renal cell carcinoma.

Authors:  M S Lima; R A Pereira; R S Costa; S Tucci; M Dantas; V F Muglia; R C Ravinal; G E Barros-Silva
Journal:  Int Urol Nephrol       Date:  2013-11-17       Impact factor: 2.370

Review 5.  The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective.

Authors:  In-Ho Kim; Hyo Jin Lee
Journal:  Biomedicines       Date:  2022-01-24

6.  Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.

Authors:  Eva Juengel; Johanna Engler; Iyad Natsheh; Jon Jones; Ausra Mickuckyte; Lukasz Hudak; Dietger Jonas; Roman A Blaheta
Journal:  BMC Cancer       Date:  2009-05-27       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.